Market Cap 103.49M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 5.88
Forward PE 25.77
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,600
Avg Vol 69,082
Day's Range N/A - N/A
Shares Out 16.75M
Stochastic %K 10%
Beta -0.31
Analysts Strong Buy
Price Target $25.50

Company Profile

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding s...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
2836 Center Port Circle, Pompano Beach, United States
jimmythefish
jimmythefish Sep. 5 at 8:40 PM
$BSEM Accepted Poster Presentations: The Company is pleased to announce that three clinical and scientific posters have been accepted and are on display in the poster hall. Clinical Research 1. A Simple Comparison of Real-World Pressure Ulcer Data Scientific Research 2. A Direct Comparison of Processing Methods for Placental Tissue Allografts 3. A Comparison of Sterilization Methods for Dehydrated Birth Tissue “We continue to demonstrate that process matters when it comes to providing placental allografts for chronic wound care, which is supported by favorable outcomes with our BioREtain ® technology, as well as important comparisons between BioREtain ® -processed allografts vs. competitive products,” said Dr. Wendy Weston, Vice President of Research and Development for BioStem.
2 · Reply
jimmythefish
jimmythefish Sep. 5 at 7:22 PM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=4702672006670956
1 · Reply
johnnyo_44
johnnyo_44 Sep. 5 at 3:19 PM
$BSEM check out $VSTM
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 28 at 8:19 PM
$BSEM $8 incoming into the weekend!
0 · Reply
GlobalInsights
GlobalInsights Aug. 28 at 6:12 PM
$BSEM https://carolinefifemd.com/2025/08/12/medicare-audits-of-skin-substitutes/
1 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 27 at 7:13 PM
$BSEM let’s go $7 incoming!!
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 27 at 3:09 PM
$BSEM finally above $6. Avg up as we go. When next q announced this will Boom!
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 26 at 5:13 PM
$BSEM 👍
0 · Reply
GlobalInsights
GlobalInsights Aug. 24 at 4:07 PM
$BSEM $MDXG A friend just sent this to me. If you want to know how MiMedx got hosed as far as the new rules NOT being implemented last February which would have been a HUGE boost to MDXG, it just took a few million dollars paid to Trump for Trump to put a stop to the implementation. Everyone knows it just takes money to buy action from the pedo fan. https://www.nytimes.com/2025/08/07/us/politics/trump-medicare-bandages-donors.html?unlocked_article_code=1.ck8.22Es.UYTJz-iYq_SQ&smid=url-share
1 · Reply
Whiskey1679
Whiskey1679 Aug. 23 at 8:01 PM
$BSEM High Volume Stock this past week.
1 · Reply
Latest News on BSEM
No data available.
jimmythefish
jimmythefish Sep. 5 at 8:40 PM
$BSEM Accepted Poster Presentations: The Company is pleased to announce that three clinical and scientific posters have been accepted and are on display in the poster hall. Clinical Research 1. A Simple Comparison of Real-World Pressure Ulcer Data Scientific Research 2. A Direct Comparison of Processing Methods for Placental Tissue Allografts 3. A Comparison of Sterilization Methods for Dehydrated Birth Tissue “We continue to demonstrate that process matters when it comes to providing placental allografts for chronic wound care, which is supported by favorable outcomes with our BioREtain ® technology, as well as important comparisons between BioREtain ® -processed allografts vs. competitive products,” said Dr. Wendy Weston, Vice President of Research and Development for BioStem.
2 · Reply
jimmythefish
jimmythefish Sep. 5 at 7:22 PM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=4702672006670956
1 · Reply
johnnyo_44
johnnyo_44 Sep. 5 at 3:19 PM
$BSEM check out $VSTM
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 28 at 8:19 PM
$BSEM $8 incoming into the weekend!
0 · Reply
GlobalInsights
GlobalInsights Aug. 28 at 6:12 PM
$BSEM https://carolinefifemd.com/2025/08/12/medicare-audits-of-skin-substitutes/
1 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 27 at 7:13 PM
$BSEM let’s go $7 incoming!!
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 27 at 3:09 PM
$BSEM finally above $6. Avg up as we go. When next q announced this will Boom!
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 26 at 5:13 PM
$BSEM 👍
0 · Reply
GlobalInsights
GlobalInsights Aug. 24 at 4:07 PM
$BSEM $MDXG A friend just sent this to me. If you want to know how MiMedx got hosed as far as the new rules NOT being implemented last February which would have been a HUGE boost to MDXG, it just took a few million dollars paid to Trump for Trump to put a stop to the implementation. Everyone knows it just takes money to buy action from the pedo fan. https://www.nytimes.com/2025/08/07/us/politics/trump-medicare-bandages-donors.html?unlocked_article_code=1.ck8.22Es.UYTJz-iYq_SQ&smid=url-share
1 · Reply
Whiskey1679
Whiskey1679 Aug. 23 at 8:01 PM
$BSEM High Volume Stock this past week.
1 · Reply
GlobalInsights
GlobalInsights Aug. 22 at 6:33 PM
$BSEM https://carolinefifemd.com/2025/08/20/skin-substitute-kickbacks/
0 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 22 at 6:15 PM
$BSEM if this keeps dropping I am selling the house and buying everything I can! This is so ridiculous!!
0 · Reply
GlobalInsights
GlobalInsights Aug. 21 at 4:32 PM
$BSEM Yes, companies can claw back CEO stock awards (and other incentive compensation) when financial statements need to be restated. Here's why and how it works: Dodd-Frank Act and SEC Rules: Federal laws, particularly the Dodd-Frank Act, and subsequent SEC rules, mandate that public companies have policies to recover excess incentive-based compensation from executive officers in the event of a financial restatement due to material noncompliance with securities laws.
0 · Reply
GlobalInsights
GlobalInsights Aug. 21 at 3:45 PM
$BSEM Share purchase can be a positive development or a move of desperation. If 2-3 other insiders did the same thing it would sent a bigger message. I was looking at the CEO compensation in the form 10. There it says he has stock/options of 3,397,431 shares but the news announcement says he holds 1,145,362 shares. Why the difference. Maybe form 10 includes unvested shares/options? The other award which I don’t recall seeing at other companies is the award of 450k shares over 5 tranches based on exceeding a specific mkt cap over a 90 day period. CFO got the same deal. What I’m not sure of is if financial statements have to be restated does it reverse the share/options awarded and are clawed back since those shares since the were based on a false mkt cap premise if financials are restated? One possible explanation is the difference between 3.4m shares and 1.1m shares is that the 2.25m share award are on hold pending firm 10 resolution. Not sure? Check form 10 starting page 69 on comp.
0 · Reply
jimmythefish
jimmythefish Aug. 21 at 12:35 PM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=8262376439902012 CEO just bought 15000 shares for around $100,000
2 · Reply
hohumStocks
hohumStocks Aug. 20 at 6:59 PM
$BSEM Seems like an exceptional value at this price for a well managed company. Loading!
1 · Reply
IRISHMIKE1
IRISHMIKE1 Aug. 20 at 2:35 PM
$BSEM Crazy, short term blip in earnings which was explained with earnings call. Earning will be back on Track with next earningss call. I’ll use this opportunity to accumulate! When we get uplisting this will take off FAST!
0 · Reply
GlobalInsights
GlobalInsights Aug. 20 at 2:21 PM
$BSEM Part 2: Training Records: The FDA will check that employees are adequately trained on relevant procedures. Equipment Calibration and Maintenance Records: Ensuring equipment is properly maintained and calibrated is essential for consistent product quality. The inspector will compare these documents to ensure they align with regulatory requirements and industry standards.
0 · Reply
GlobalInsights
GlobalInsights Aug. 20 at 2:20 PM
$BSEM Part 1: A crucial part of the inspection is the review of various documents, including: Quality System Documentation: This includes the quality policy, management representative, deviation reports, management review records, internal audit reports, quality plans, and CAPA (Corrective and Preventive Action) procedures. Device History Records (DHR): These records document the entire production history of a specific device, including dates, times, personnel involved, and processes followed. Standard Operating Procedures (SOPs): These are detailed instructions for how various manufacturing processes should be performed, and the FDA will compare these to the DHRs. Non-Conformance and CAPA Reports: These reports detail any deviations from standard procedures and the actions taken to correct them. Validation and Verification Reports: These reports demonstrate that the manufacturing processes consistently produce devices that meet specifications.
0 · Reply
GlobalInsights
GlobalInsights Aug. 20 at 2:12 PM
$BSEM A medical product manufacturer's quality system is a structured framework that ensures the safety and effectiveness of medical devices throughout their lifecycle. It involves a comprehensive set of policies, procedures, and processes that govern all aspects of the business, from design and development to manufacturing, distribution, and post-market surveillance. Key elements include quality planning, design control, risk management, production control, and corrective and preventive action (CAPA).
0 · Reply
GlobalInsights
GlobalInsights Aug. 20 at 2:10 PM
$BSEM Its still not clear why the FDA warning letter has not been closed. I understand that the products mentioned are no longer being mfg and sold. However anyone that knows how to run a medical company knows the process and procedures used are driven by the companies quality system. The problems identified seem to me to indicate there are issues with their quality system that need to be fixed and reinspected for the whole organization. To date there is not a warning close out letter posted to the FDA website for BSEM. Also on the latest cc no mention of the status of the warning letter and when it will be closed out. Just another example of the leaderships lack of transparency with shareholders, which drives trust in mgmt to be upfront with the owners of the business, the shareholders.
0 · Reply
Monk1212
Monk1212 Aug. 19 at 2:48 PM
$BSEM CMS is more likely to implement fraud controls and extra documentation requirements, which BioStem can easily manage thanks to its transparent practices and clinical data. For shareholders, this uncertainty is what’s keeping the stock price down — not company fundamentals. Once CMS provides clarity, BioStem’s shares could see a sharp rebound, especially with catalysts like its diabetic foot ulcer program, expanding product portfolio, and distribution partnerships. This is why many investors view the current weakness as a long-term buying opportunity rather than a reason to exit.
1 · Reply